Edgewise Therapeutics, Inc. EWTX
Updated: 11 Aug 2026
No signal published yet
We already track Edgewise Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Edgewise Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Edgewise Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 6, 2026, Edgewise Therapeutics reported its second quarter 2026 financial results, highlighting positive Phase 2 trial data for EDG-7500 in hypertrophic cardiomyopathy. In July 2026, the company completed the sale of its muscular dystrophy business to Servier for $1.55 billion in upfront cash. The deal significantly strengthened the company's balance sheet as it sharpens focus on its cardiovascular pipeline.
What Firelda Watch includes for Edgewise Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Edgewise Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Edgewise Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more